Work

Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities

Year: 2011

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v118.21.608.608

Authors: Guillermo Garcia-Manero, Elihu H Estey, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Kiran Naqvi, Ross L Levine, Zeev Estrov, Alfonso Quintas-Cardama, Marina Konopleva, Stefan Faderl, Maria Tanaka, Hui Yang, Farhad Ravandi, William G. Wierda, Jorge E. Cortes, Patricia Ann Boone, Hagop M. Kantarjian

Institutions: The University of Texas MD Anderson Cancer Center, University of Washington, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, Baylor College of Medicine

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2561700492

FWCI: 3.582

Cites:

Cited by: 26

Related to: 10